Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$38.21 USD
-1.73 (-4.33%)
Updated May 17, 2024 04:00 PM ET
After-Market: $38.20 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 181 - 200 ( 412 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; More Focus on Varli and Glemba
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q, CLDX Tightens Focus Post-Rindo, Lowering PT to $3 CDX-301 Development Strategy Changes, Reiterate N
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Glemba; Varli Shows Early Promise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology AACR Roundup for Covered Companies.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Varli Safety Profile Building; Into Phase II Portion with Opdivo Combo
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
End of an ACT But Celldex Goes On; Reiterate Buy; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Real Crappy Way to Be Wrong; Removing from Focus List; Target to $7
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Lowering PT to $4; Rindopepimut Fails Second Interim of ACT IV
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating our coverage with a Buy rating and a $25.00 price target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; The Growing Excitement Is Palpable; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q15 Earnings and 2016 Outlook, Focus is on ACT IV Interim Announcement in March, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We''re Prepped for ACT IV Interim and Beyond; It''s All About Consistency
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J